-
ASH 2024 | Dr. Huiqiang Huang Discusses Groundbreaking Lymphoma Research with Dr. Jun Zhu
The 2024 American Society of Hematology (ASH) Annual Meeting took place in San Diego from December 7 to 10, attracting the global hematology community’s attention. As one of the most prestigious international events in the field, this conference has drawn keen interest from researchers and clinicians worldwide, including those in China. To provide timely updates…
-
ASH 2024丨Dr. Jing Pan: Applications of CAR-T Therapy in R/R T-ALL and B-ALL, Prognostic Factors, and a Stratified CAR-T Treatment Framework
The 66th American Society of Hematology (ASH) Annual Meeting was held in San Diego, USA, from December 7–10, 2024. Renowned as the largest and most comprehensive international academic event in the field of hematology, the conference gathers leading experts and researchers worldwide to discuss and exchange groundbreaking advancements in hematology. At this year’s meeting, the…
-
ASH 2024 | Dr. Qian Jiang: Groundbreaking Leukemia Research and the Future of the Field
Dr. Qian Jiang: I’m delighted to share the results of our team’s work presented at this year’s ASH meeting. Our Phase 1 clinical trial on the BCR::ABL1 allosteric inhibitor TGRX-678…
-
ASH 2024 | Dr. Wenming Chen: Precision and Immune-Targeted Therapies to Overcome R/R MM Challenges
Abstract #4762 Subgroup Analyses of Phase 2 Study: Evaluating Fully Human BCMA CAR-T Therapy (Zevorcabtagene Autoleucel) for R/R MM Dr. Wenming Chen:At the 2021 ASH meeting, the Phase 1 results…
-
Professor Dingwei Ye: Advancing Innovation in Uro-Oncology from Bench to Bedside, Sharing Chinese Expertise to Benefit Global Patients
In recent years, breakthroughs in basic research and clinical trials, particularly in combined targeted and immunotherapy strategies and the development of domestically produced novel drugs, have significantly advanced clinical practices in uro-oncology. However, transforming cutting-edge research into practical clinical applications and sharing Chinese expertise with international patients remains an ongoing challenge. The 14th Shanghai Genitourinary…
-
ASH 2024 | Dr. Jun Shi: Landmark Findings in Lymphoma—No Benefit of Auto-HCT in First CR with uMRD in MCL, and R-CHOP-like Regimens Effective for Advanced Relapsed DLBCL
The 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10 in San Diego, remains the largest and most comprehensive international academic gathering in the field of hematology. Every year, it draws leading experts and scholars from across the globe for in-depth discussions and exchanges on groundbreaking research. This year, the…
-
ASH 2024 | Dr. Huaquan Wang: Latest Advances in the Treatment of Low-Risk MDS (Part 2)
Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal disorders originating from hematopoietic stem cells, characterized by dysplastic development of myeloid cells, ineffective hematopoiesis, refractory cytopenia, and a potential progression to acute myeloid leukemia (AML). At the 2024 Annual Meeting of the American Society of Hematology (ASH), held from December 7 to 10 in…
-
ASH 2024 | Dr. Wenming Chen Discusses Key Myeloma Research
The 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10 in San Diego, continues to be a global focal point for clinicians and researchers in hematology. As one of the most prestigious international conferences in the field, it has captured widespread attention both globally and within China. To provide timely…
Connecting Medical Expertise through Media